Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition
about
Chimeric antigen receptor T-cell therapy for solid tumorsMesothelin-Targeted CARs: Driving T Cells to Solid TumorsAdoptive T-Cell ImmunotherapyAdoptive cell therapy for sarcomaImproving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer VaccinationTherapeutic cancer vaccines and combination immunotherapies involving vaccinationInterleukin-7 and Immunosenescence.K562-Derived Whole-Cell Vaccine Enhances Antitumor Responses of CAR-Redirected Virus-Specific Cytotoxic T Lymphocytes In Vivo.Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell TherapyIL-7 signaling imparts polyfunctionality and stemness potential to CD4(+) T cells.Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy.Chimeric antigen receptor-redirected T cells return to the benchElevated systemic interleukin-7 in patients with colorectal cancer and individuals at high risk of cancer: association with lymph node involvement and tumor location in the right colon.Advances in chimeric antigen receptor immunotherapy for neuroblastoma.CD28z CARs and armored CARsGoing viral: chimeric antigen receptor T-cell therapy for hematological malignancies.New immunotherapeutic strategies for the treatment of neuroblastoma.Exploiting cytokines in adoptive T-cell therapy of cancer.Chimeric Antigen Receptor (CAR) therapy for multiple myeloma.Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers.Chimeric antigen receptors: driving immunology towards synthetic biology.Development of CAR T cells designed to improve antitumor efficacy and safety.CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond.Adjuvant IL-7 potentiates adoptive T cell therapy by amplifying and sustaining polyfunctional antitumor CD4+ T cellsPractical considerations for chimeric antigen receptor design and delivery.Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy.Interleukin-armed chimeric antigen receptor-modified T cells for cancer immunotherapy.Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications.PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells.Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma.The perioperative dynamics of IL-7 following robot-assisted and open colorectal surgery.
P2860
Q26750908-E37A46B4-59D8-4DCC-B5B1-6A69D769F8F9Q26778759-596F854C-1C29-4531-B71E-A2F9C725D305Q26782845-0C3A4176-48C2-42C4-880F-0B7C4CBB2F21Q27009541-FD325099-95FF-4CE0-900C-7CC0EDF46B84Q28068378-A03509F9-00DE-43EE-8DE6-A012DC8314E9Q28397609-7B8B080A-7170-4E73-9029-62D0260ABAD0Q33582101-38D561B1-C02B-4F1E-A59F-BB305E7BA1BCQ35812085-6CDB7207-235E-4EE0-880A-63D4CC088034Q36173500-1B3161F7-4654-43F7-A83D-C0DDA2DC4383Q37078985-1F080220-D488-459A-B640-B022426DA630Q37163445-E63C641D-A27F-4B44-9C3F-A9C83E4708C8Q37301510-3C86129B-38D7-4729-B88C-547BD6B2CBA7Q37614711-9605DA0F-AE41-445F-804D-8E8AD9F2425DQ38170885-67FE716A-DF18-4DAA-A3BC-06F06A247FF9Q38199347-C6EA1012-FA87-4954-AEC8-4962F1BD8CB7Q38289029-C79A2623-542C-4649-B3D4-C6454A81D75FQ38389316-1A4BA13A-CC40-419D-92EF-240CFB07E22CQ38525044-41E1BA7E-0440-45C8-A0AE-EF01FEB3A73FQ38704573-4D0CB066-2ED9-4E1E-9106-C8FEFE66F3CDQ38786626-129BD61E-E885-4EC2-BB3B-D0AF2348D919Q38810926-A8E3DC57-8252-448A-B7AC-3E9D3F2207B1Q38884383-3B8ED09C-0475-47E0-976F-2CCEED018D34Q39200527-5D9E2357-D834-444C-8026-5F6328E2E6CEQ39246685-C1D24014-E8E8-49BF-B37E-BBDCC2F70BDFQ42362935-490D7D3B-7F10-45F1-839A-EC3703F4F5E3Q45868559-E5EAD85F-2212-43BB-9D80-07E89E514405Q45870279-28F18EC6-6787-46AB-BB8C-A7AC15F605B3Q45870945-139DD8BC-5788-48F6-844B-9CC73712BCC0Q47561397-AEAB5AEA-8734-4908-BAED-2332AABDE3BEQ47920923-BD06449B-0751-4DCE-AA21-95C6E38346B1Q55216432-E81DCD89-7E55-4E0C-A025-1B0A87D2529DQ55381850-2C7BD36B-FD83-499B-AE43-9A53A36D0452
P2860
Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Interleukin-7 mediates selecti ...... f regulatory T-cell inhibition
@en
Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes
@nl
type
label
Interleukin-7 mediates selecti ...... f regulatory T-cell inhibition
@en
Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes
@nl
prefLabel
Interleukin-7 mediates selecti ...... f regulatory T-cell inhibition
@en
Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes
@nl
P2093
P2860
P1476
Interleukin-7 mediates selecti ...... f regulatory T-cell inhibition
@en
P2093
Aruna Mahendravada
Barbara Savoldo
Daria Pagliara
Gianpietro Dotti
Malcolm K Brenner
Serena K Perna
P2860
P304
P356
10.1158/1078-0432.CCR-13-1016
P407
P577
2013-10-04T00:00:00Z